2015-2016 vaccine effectiveness of live attenuated and inactivated influenza vaccines in children in the United States

Clinical Infectious Diseases

Volumn 66, Issue 5, 2018, Pages 665-672

  Poehling, Katherine A ⁱ   Caspard, Herve ^a   Peters, Timothy R ⁱ   Belongia, Edward A ^b   Congeni, Blaise ^c   Gaglani, Manjusha ^d   Griffin, Marie R ^e   Irving, Stephanie A ^f   Kavathekar, Poornima K ^g   McLean, Huong Q ^b   Naleway, Allison L ^f   Ryan, Kathleen ^h   Keipp Talbot, H ^e   Ambrose, Christopher S ^a  

^a MEDIMMUNE   (United States)

^b MARSHFIELD CLINIC   (United States)

^c AKRON CHILDREN'S HOSPITAL   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f CENTER FOR HEALTH RESEARCH   (United States)

^g HEALTHPARTNERS INSTITUTE   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Influenza; Influenza vaccine; Vaccine effectiveness

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; VACCINE;

ADOLESCENT; ARTICLE; CASE CONTROL STUDY; CHILD; COUGHING; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HUMAN; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE SMEAR; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINORRHEA; SORE THROAT; UNITED STATES; VACCINE FAILURE; VOMITING; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; NOSE; SEASON; STATISTICAL MODEL; VACCINATION; VIROLOGY;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; NOSE; SEASONS; UNITED STATES; VACCINATION; VACCINE POTENCY; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 85045929231     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix869     Document Type: Article

References (33)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-96.
2. Fowlkes A, Steffens A, Temte J, et al; Influenza Incidence Surveillance Project Working Group. Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. Lancet Respir Med 2015; 3:709-18.
3. Schanzer D, Vachon J, Pelletier L. Age-specific differences in influenza A epidemic curves: do children drive the spread of influenza epidemics? Am J Epidemiol 2011; 174:109-17.
4. Peters TR, Snively BM, Suerken CK, Blakeney E, Vannoy L, Poehling KA. Relative timing of influenza disease by age group. Vaccine 2014; 32:6451-6.
5. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1-60.
6. Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States. Vaccine 2016; 34:61-6.
7. Davis MM, King JC Jr, Moag L, Cummings G, Magder LS. Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008; 122:e260-5.
8. Loeb M, Russell ML, Manning V, et al. Live attenuated versus inactivated influenza vaccine in Hutterite children: a cluster randomized blinded trial. Ann Intern Med 2016; 165:617-24.
9. Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine 2016; 34:77-82.
10. McLean HQ, Caspard H, Griffin MR, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine 2017; 35:2685-93.
11. Ashkenazi S, Vertruyen A, Arístegui J, et al; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9.
12. Belshe RB, Edwards KM, Vesikari T, et al; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
13. Fleming DM, Crovari P, Wahn U, et al; CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents. Pediatr Infect Dis J 2006; 25:860-9.
14. Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016; 137:e20153279.
15. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis 2016; 213:1546-56.
16. Davlin SL, Blanton L, Kniss K, et al. Influenza Activity-United States, 2015-16 season and composition of the 2016-17 influenza vaccine. MMWR Morb Mortal Wkly Rep 2016; 65:567-75.
17. Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States-2015/16 season. N Engl J Med 2017; 377:534-43.
18. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep 2015; 64:818-25.
19. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
20. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
21. Griffin MR, Monto AS, Belongia EA, et al; U.S. Flu-VE Network. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011; 6:e23085.
22. Uzicanin A, Thompson M, Smith P, et al. Effectiveness of 1 dose of influenza A(H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 inflection among school-aged children in Maine. J Infect Dis 2012; 206:1059-68.
23. Eick-Cost AA, Tastad KJ, Guerrero AC, et al. Effectiveness of seasonal influenza vaccines against influenza-associated illnesses among US military personnel in 2010-11: a case-control approach. PLoS One 2012; 7:e41435.
24. Caspard H, Coelingh KL, Mallory RM, Ambrose CS. Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States. Vaccine 2016; 34:5066-72.
25. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds-a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill 2016; 21:30346.
26. Skowronski D. Live attenuated influenza vaccine (LAIV) vs. inactivated influenza vaccine (IIV): summary of effectiveness evidence since 2009. In: Program and abstracts of the National Advisory Committee on Immunization, Influenza Working Group, Ottawa, Ontario. (Updated 2016.) Available at: http://www.phac-aspc.gc.ca/naci-ccni/flu-2016-grippe-addendum-children-enfants-eng. php. Accessed 28 March 2017.
27. Helmeke C. Effektivität der influenza-impfstoffe bei kindern in Sachsen-Anhalt und Niedersachsen 2015/16. Available at: http://www.verbraucherschutz.sachsen-anhalt.de/fileadmin/Bibliothek/Politik_und_Verwaltung/ MS/LAV_Verbraucherschutz/hygiene/influenza/Effektivitaet_der_ Influenzaimpfstoffe_2015-16.pdf. Accessed 6 February 2017.
28. Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill 2016; 21:30348.
29. Flannery B, Chung J. Influenza vaccine effectiveness, including LAIV vs IIV in children and adolescents, US Flu VE Network, 2015-16. Presented at the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) Meeting, 22-23 June 2016, Atlanta, GA. Available at: https:// www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influen-za-05-flannery.pdf. Accessed 6 February 2017.
30. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2016; 65:1-54.
31. Pebody R, Sile B, Warburton F, et al. Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. Euro Surveill 2017; 22:pii: 30450
32. National Services Scotland. Flu vaccine effectiveness in Scottish primary school age children from the 2015/2016 season. Available at: http://www.hps.scot.nhs.uk/resourcedocument.aspx?id=5529. Accessed 6 February 2017.
33. Broberg E, Melidou A, Prosenc K, Bragstad K, Hungnes O, on behalf of the WHO European Region and the European Influenza Surveillance Network members of the reporting countries: predominance of influenza A(H1N1) pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. Euro Surveill 2016; 21:pii=30184.